Barclays analyst Luke Sergott lowered the firm’s price target on Thermo Fisher to $585 from $625 and keeps an Overweight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Spotify downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
- Thermo Fisher initiated with an Outperform at Bernstein
- ‘Load Up,’ Says Morgan Stanley About These 3 ‘Strong Buy’ Stocks
- White House to resume offering free at-home COVID tests in U.S., CNBC says
- Thermo Fisher, Devyser enter agreement to promote laborator services